Credit Suisse’s NovoCure NVCR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | $13.2M | Sell |
847,520
-5,996
| -0.7% | -$88.2K | 0.01% | 794 |
|
|
2023
Q4 | $12.7M | Buy |
853,516
+28,557
| +3% | +$382K | 0.01% | 815 |
|
|
2023
Q3 | $13.3M | Buy |
824,959
+7,223
| +0.9% | +$208K | 0.01% | 784 |
|
|
2023
Q2 | $33.9M | Sell |
817,736
-59,952
| -7% | -$3.72M | 0.03% | 506 |
|
|
2023
Q1 | $52.8M | Sell |
877,688
-82,358
| -9% | -$6.58M | 0.05% | 379 |
|
|
2022
Q4 | $70.4M | Sell |
960,046
-119,050
| -11% | -$8.96M | 0.07% | 284 |
|
|
2022
Q3 | $82M | Sell |
1,079,096
-1,140
| -0.1% | -$88.9K | 0.09% | 229 |
|
|
2022
Q2 | $75.1M | Sell |
1,080,236
-282,747
| -21% | -$21.3M | 0.08% | 265 |
|
|
2022
Q1 | $113M | Buy |
1,362,983
+1,660
| +0.1% | +$122K | 0.1% | 218 |
|
|
2021
Q4 | $102M | Sell |
1,361,323
-23,028
| -2% | -$2.31M | 0.05% | 354 |
|
|
2021
Q3 | $161M | Buy |
1,384,351
+114,847
| +9% | +$17.4M | 0.09% | 222 |
|
|
2021
Q2 | $282M | Sell |
1,269,504
-363,347
| -22% | -$70.7M | 0.15% | 128 |
|
|
2021
Q1 | $216M | Buy |
1,632,851
+178,392
| +12% | +$28.2M | 0.11% | 187 |
|
|
2020
Q4 | $252M | Sell |
1,454,459
-192,511
| -12% | -$26.3M | 0.12% | 156 |
|
|
2020
Q3 | $183M | Sell |
1,646,970
-550,890
| -25% | -$44.1M | 0.11% | 185 |
|
|
2020
Q2 | $130M | Buy |
2,197,860
+913,568
| +71% | +$60.1M | 0.09% | 215 |
|
|
2020
Q1 | $86.5M | Buy |
1,284,292
+323,594
| +34% | +$25.6M | 0.07% | 260 |
|
|
2019
Q4 | $81M | Sell |
960,698
-37,673
| -4% | -$3.04M | 0.06% | 359 |
|
|
2019
Q3 | $74.7M | Sell |
998,371
-187,216
| -16% | -$15M | 0.06% | 314 |
|
|
2019
Q2 | $75M | Buy |
1,185,587
+3,777
| +0.3% | +$191K | 0.07% | 301 |
|
|
2019
Q1 | $56.9M | Sell |
1,181,810
-305,761
| -21% | -$14.7M | 0.05% | 371 |
|
|
2018
Q4 | $49.8M | Buy |
1,487,571
+541,917
| +57% | +$19.8M | 0.05% | 384 |
|
|
2018
Q3 | $49.6M | Buy |
945,654
+440,543
| +87% | +$17.5M | 0.04% | 428 |
|
|
2018
Q2 | $15.8M | Buy |
505,111
+415,809
| +466% | +$11.6M | 0.02% | 966 |
|
|
2018
Q1 | $1.95M | Buy |
89,302
+38,255
| +75% | +$823K | ﹤0.01% | 2448 |
|
|
2017
Q4 | $1.03M | Sell |
51,047
-15,664
| -23% | -$302K | ﹤0.01% | 2969 |
|
|
2017
Q3 | $1.32M | Buy |
66,711
+30,017
| +82% | +$590K | ﹤0.01% | 2893 |
|
|
2017
Q2 | $635K | Buy |
36,694
+12,280
| +50% | +$159K | ﹤0.01% | 2982 |
|
|
2017
Q1 | $197K | Sell |
24,414
-15,848
| -39% | -$114K | ﹤0.01% | 3624 |
|
|
2016
Q4 | $315K | Buy |
40,262
+10,354
| +35% | +$83.3K | ﹤0.01% | 3639 |
|
|
2016
Q3 | $255K | Sell |
29,908
-1,767
| -6% | -$16.1K | ﹤0.01% | 3718 |
|
|
2016
Q2 | $370K | Buy |
+31,675
| New | +$397K | ﹤0.01% | 3585 |
|
Other funds holding NVCR
Credit Suisse's NVCR Position: Q1 2024 in Review
Credit Suisse reduced its NovoCure (NVCR) stake by 0.7% in Q1 2024, selling an estimated $88.2K and leaving 847,520 shares worth $13.2M. The position accounts for 0.01% of the portfolio, ranked #794.
Credit Suisse first reported a position in NVCR in Q2 2016 and has held it in 32 quarters since. The position peaked at $282M in Q2 2021. 237 funds tracked by Wall St. Rank hold NVCR as of Q1 2024.
- Credit Suisse held 847,520 shares of NovoCure worth $13.2M as of Q1 2024.
- Credit Suisse sold 5,996 NovoCure shares in Q1 2024, an estimated $88.2K.
- NovoCure made up 0.01% of Credit Suisse's portfolio in Q1 2024, its #794 holding.
- Credit Suisse first reported a position in NovoCure in Q2 2016 and has held it in 32 quarters since.
- Credit Suisse's NovoCure position peaked at $282M in Q2 2021.
- 237 funds tracked by Wall St. Rank held NovoCure as of Q1 2024.
Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.